Promising first-in-class and potential medical breakthrough pipeline projects presented at R&D Press Conference• 80 clinical and pre-clinical projects of which 65% have first-in-class and breakthrough potential • Highlight: First-in-class monoclonal antibody shows potential in multiple inflammatory diseases• 15 new medicines could potentially be approved by 2025 in immunology, CNS, oncology, respiratory and cardiometabolic diseases
26 April, 2018
Expansion significantly increases laboratory space, creating new job opportunities in the area
26 April, 2018
Pioneering medical technology company, Elucigene Diagnostics, has been awarded the UK’s most prestigious honour for outstanding success in international trade: the Queen’s Award for Enterprise.
24 April, 2018